Medytox Begins Mass Production of 'Coretox', Botulinum Toxin with Non-Toxic Protein Removed

Lowering the Possibility of Resistance Emergence... Additional Manufacturing Site Added to Plant 3 at the End of Last Year

Medytox Coretox.

[Asia Economy Reporter Lee Gwan-joo] Medytox announced on the 20th that it has started mass production of 'Coretox,' the only botulinum toxin product in Korea that reduces the possibility of resistance by removing non-toxic proteins.

Medytox has been building a mass production system for Coretox, which was previously produced only at the Ochang Plant 1, following the approval of an additional manufacturing facility at Plant 3 at the end of last year, and recently began full-scale operation.

Developed by Medytox in 2016, 'Coretox' is the only botulinum toxin product in Korea and the second in the world to be developed by removing non-toxic proteins, one of the causes of resistance, from the existing 900kDa toxin formulation, containing only 150kDa neurotoxin. Additionally, it has strengths such as using only non-animal culture media during strain cultivation to reduce infection risk and not using human serum albumin (HSA) as a stabilizer.

Although Medytox succeeded in developing three types of toxin products, Plant 3, which has an annual production scale exceeding 600 billion KRW, has focused solely on producing 'Medytoxine.' However, as the toxin market grows and concerns about resistance increase, Medytox received approval from the Ministry of Food and Drug Safety (MFDS) at the end of last year to add a manufacturing facility for Coretox at Plant 3, completing a dual production system for both 'Medytoxine' and 'Coretox.'

Joo Hee-seok, Vice President of Medytox, stated, "Currently, the botulinum toxin market is divided based on price, but in the future, the presence or absence of non-toxic proteins that cause resistance will become a new criterion for market segmentation. We plan to accelerate mass production of Coretox to simultaneously achieve increased sales and enhanced corporate recognition."

Meanwhile, Medytox is accelerating the development of new botulinum toxin products alongside existing ones. Recently, Medytox's affiliate Medytox Korea completed the Phase 3 clinical trial of 'MBA-P01' in Korea and announced plans to apply for approval in May.

This content was produced with the assistance of AI translation services.